CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's disease

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5033-5037

  Lora, Viviana ^a   Kanitakis, Jean ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

CDX2; Cutaneous metastases; Extramammary Paget's disease; Immunohistochemistry; Skin

Indexed keywords

TRANSCRIPTION FACTOR CDX2;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAGET SKIN DISEASE; PRIORITY JOURNAL; SKIN BIOPSY;

COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM STAGING; PAGET DISEASE EXTRAMAMMARY; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 75149176259     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kanitakis J: Les métastases cutanées des cancers profonds. Presse Med 22: 631-636, 1993.
2. Schwartz RA and Smith B: Histopathologic aspects of cutaneous metastatic disease. J Am Acad Dermatol 33: 649-657, 1995.
3. Sariya D, Ruth K, Adams-McDonnell R, Cusack C, Xu X, Elenitsas R, Seykora J, Pasha T, Zhang P, Baldassano M, Lessin SR and Wu H: Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol 143: 613-620, 2007.
4. Chu P, Wu E and Weiss L: Cytokeratins 7 and cytokeratin 20 expression in epithelial neoplasms; a survey of 435 cases. Mod Pathol 13: 962-972, 2000.
5. Leroy X, Copin MC, Boman F and Gosselin B: Cytokeratins 7 and 20: aid in tumor typing. Ann Pathol 18: 103-109, 1998.
6. Freund J-N, Domon-Dell C, Kedinger M and Duluc I: The CDX-1 and CDX-2 homeobox genes in the intestine. Biochem Cell Biol 76: 957-969, 1998.
7. Drummond F, Putt W, Fox M and Edwards YH: Cloning and chromosome assingment of the human CDX2 gene. Ann Hum Genet 61: 393-400, 1997.
8. Li MK and Folpe AL: CDX-2, a new marker for adenocarcinoma of gastrointestinal origin. Adv Anat Pathol 11: 101-105, 2004.
9. Werling RW, Yaziji H, Bacchi CE and Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27: 303-310, 2003.
10. Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M and Doglioni C: CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 27: 141-149, 2003.
11. Kaimaktchiev V, Teraciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G and Corless CL: The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 17: 1392-1399, 2004.
12. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR and Fearon ER: Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 159: 2239-2248, 2001.
13. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM and Frierson HF Jr: CDX2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 16: 913-919, 2003.
14. Saad R, Silverman J, Khalifa M and Rowsell C: CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 17: 196-201, 2009.
15. Saad RS, Ismii N, Dubé V, Nofech-Mozes S and Khalifa MA: CDX2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol 132: 531-538, 2009.
16. -phenotype. Med Sci Monit 10: BR139-143, 2004.
17. De Nisi MC, D'Amuri A, Toscano M, Lalinga AV, Pirtoli L and Miracco C: Usefulness of CDX2 in the diagnosis of extramammary Paget disease associated with malignancies of intestinal type. Br J Dermatol 153: 677-679, 2005.
18. Zeng HA, Cartun R and Ricci A Jr: Potential diagnostic utility of CDX-2 immunophenotyping in extramammary Paget's disease. Appl Immunohistochem Mol Morphol 13: 342-346, 2005.
19. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS and Ogino S: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15: 4665-4673, 2009.
20. Witek M, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S and Waldan SA: The putative tumor suppressor CDX2 is overexpressed by human colorectal adenocarcinoma. Clin Cancer Res 11: 8549-8556, 2005.
21. Dang LH, Chen F, Ying C, Chun SY, Knock SA, Appelman HD, Dang DT: CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48. Oncogene 25: 2264-2272, 2006.
22. Mazziotta R, Borczuk A, Powell CA and Mansukhani M: CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immmunohistochem Mol Morphol 13: 55-60, 2005.
23. Kanitakis J: Mammary and extramammary Paget's disease. J Eur Acad Dermatol Venereol 21: 581-590, 2007.